home / stock / acxp / acxp quote
Last: | $2.01 |
---|---|
Change Percent: | 1.39% |
Open: | $2.13 |
Close: | $2.01 |
High: | $2.185 |
Low: | $2.01 |
Volume: | 20,303 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.01 | $2.13 | $2.01 | $2.185 | $2.01 | 20,303 | 07-03-2024 |
$2.16 | $2.16 | $2.16 | $2.3 | $2.07 | 50,223 | 07-02-2024 |
$2.14 | $2.23 | $2.14 | $2.25 | $2.14 | 23,471 | 07-01-2024 |
$2.25 | $2.34 | $2.25 | $2.35 | $2.19 | 32,420 | 06-28-2024 |
$2.31 | $2.27 | $2.31 | $2.4 | $2.16 | 36,951 | 06-27-2024 |
$2.24 | $2.22 | $2.24 | $2.27 | $2.16 | 19,090 | 06-26-2024 |
$2.17 | $2.27 | $2.17 | $2.3 | $2.17 | 18,637 | 06-25-2024 |
$2.28 | $2.33 | $2.28 | $2.4 | $2.28 | 20,493 | 06-24-2024 |
$2.33 | $2.255 | $2.33 | $2.43 | $2.2206 | 58,286 | 06-21-2024 |
$2.23 | $2.25 | $2.23 | $2.32 | $2.2077 | 18,125 | 06-20-2024 |
$2.25 | $2.42 | $2.25 | $2.42 | $2.25 | 51,710 | 06-19-2024 |
$2.25 | $2.42 | $2.25 | $2.42 | $2.25 | 51,710 | 06-18-2024 |
$2.38 | $2.45 | $2.38 | $2.45 | $2.36 | 18,447 | 06-17-2024 |
$2.43 | $2.43 | $2.43 | $2.48 | $2.3551 | 46,325 | 06-14-2024 |
$2.48 | $2.49 | $2.48 | $2.49 | $2.322 | 37,789 | 06-13-2024 |
$2.49 | $2.6 | $2.49 | $2.6168 | $2.46 | 15,582 | 06-12-2024 |
$2.55 | $2.4 | $2.55 | $2.56 | $2.3928 | 24,798 | 06-11-2024 |
$2.4 | $2.42 | $2.4 | $2.565 | $2.34 | 33,485 | 06-10-2024 |
$2.4 | $2.39 | $2.4 | $2.4171 | $2.273 | 19,592 | 06-07-2024 |
$2.37 | $2.45 | $2.37 | $2.5 | $2.335 | 29,521 | 06-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
Acurx Pharmaceuticals Inc. Company Name:
ACXP Stock Symbol:
NASDAQ Market:
Acurx Pharmaceuticals Inc. Website:
NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street announces the broadcasting of its national business TV show airing on Bloomberg TV as sponsored programming tonight, Thursday, June 6, 2024, at 9:30 PM PT. New to The Street's TV episode 576 will air the follo...
Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection PR Newswire Agreement with FDA reached on key elements to move forward with our international Phase 3 clinical trial program Agreement al...
Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update PR Newswire STATEN ISLAND, N.Y. , May 15, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a clinical stage biophar...